|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: Challenges and interventions. Chest.
143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
7
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roudi R, Madjd Z, Korourian A, Mehrazma M,
Molanae S, Sabet MN and Shariftabrizi A: Clinical significance of
putative cancer stem cell marker CD44 in different histological
subtypes of lung cancer. Cancer Biomark. 14:457–467. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu
HS and Hung SC: IL-6 enriched lung cancer stem-like cell population
by inhibition of cell cycle regulators via DNMT1 upregulation. Int
J Cancer. 136:547–559. 2015.PubMed/NCBI
|
|
11
|
Zhou BB, Zhang HY, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug
Discovery. 8:806–823. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohman R and Axelsson R: Relationship
between prolactin response and antipsychotic effect of thioridazine
in psychiatric-patients. Eur J Clin Pharmacol. 14:111–116. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Realmuto GM, Erickson WD, Yellin AM,
Hopwood JH and Greenberg LM: Clinical comparison of thiothixene and
thioridazine in schizophrenic adolescents. Am J Psychiatry.
141:440–442. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Soolingen D, Hernandez-Pando R, Orozco
H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J and Boeree MJ:
The antipsychotic thioridazine shows promising therapeutic activity
in a mouse model of multidrug-resistant tuberculosis. PLoS One.
5:e126402010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thorsing M, Klitgaard JK, Atilano ML, Skov
MN, Kolmos HJ, Filipe SR and Kallipolitis BH: Thioridazine induces
major changes in global gene expression and cell wall composition
in methicillin-resistant Staphylococcus aureus USA300. PLoS One.
8:e645182013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagel D, Spranger S, Vincendeau M, Grau M,
Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, von Kries J
Peter, Hadian K, et al: Pharmacologic inhibition of MALT1 protease
by phenothiazines as a therapeutic approach for the treatment of
aggressive ABC-DLBCL. Cancer Cell. 22:825–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Byun HJ, Lee JH, Kim BR, Kang S, Dong SM,
Park MS, Lee SH, Park SH and Rho SB: Anti-angiogenic effects of
thioridazine involving the FAK-mTOR pathway. Microvascular Res.
84:227–234. 2012. View Article : Google Scholar
|
|
18
|
Park MS, Dong SM, Kim BR, Seo SH, Kang S,
Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and
tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian
cancer xenografts. Oncotarget. 5:4929–4934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Csonka A, Spengler G, Martins A, Ocsovszki
I, Christensen JB, Hendricks O, Kristiansen JE, Amaral L and Molnar
J: Effect of thioridazine stereoisomers on the drug accumulation of
mouse lymphoma and human prostate cancer cell lines in vitro. In
vivo. 27:815–820. 2013.PubMed/NCBI
|
|
21
|
Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M,
Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic
drug, elicits potent antitumor effects in gastric cancer. Oncol
Rep. 31:2107–2114. 2014.PubMed/NCBI
|
|
22
|
Spengler G, Molnar J, Viveiros M and
Amaral L: Thioridazine induces apoptosis of multidrug-resistant
mouse lymphoma cells transfected with the human ABCB1 and inhibits
the expression of P-glycoprotein. Anticancer Res. 31:4201–4205.
2011.PubMed/NCBI
|
|
23
|
Sudo M, Mori S, Madan V, Yang H, Leong G
and Koeffler HP: Short-hairpin RNA library: Identification of
therapeutic partners for gefitinib-resistant non-small cell lung
cancer. Oncotarget. 6:814–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sachlos E, Risueño Ruth M, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick
JL and Yang YY: Co-delivery of thioridazine and doxorubicin using
polymeric micelles for targeting both cancer cells and cancer stem
cells. Biomaterials. 35:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Y, Xu HN, Huang WD, Ding M, Xiao J,
Yang D, Li H, Liu XY and Chu L: Targeting lung cancer stem-like
cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med.
19:915–923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Korkaya H, Paulson A, Charafe-Jauffret E,
Ginestier C, Brown M, Dutcher J, Clouthier SG and Wicha MS:
Regulation of mammary stem/progenitor cells by
PTEN/Akt/beta-catenin signaling. PLoS Biol. 7:e10001212009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang XL, Jia Q, Lv L, Deng T and Gao J:
Tumorspheres derived from HCC Cells are enriched with cancer stem
cell-like cells and present high chemoresistance dependent on the
Akt pathway. Anticancer Agents Med Chem. 15:755–763. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arguello PA and Gogos JA: A signaling
pathway AKTing up in schizophrenia. J Clin Investig. 118:2018–2021.
2008.PubMed/NCBI
|
|
30
|
Rho SB, Kim BR and Kang S: A gene
signature-based approach identifies thioridazine as an inhibitor of
phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer
cells. Gynecol Oncol. 120:121–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dongmei D, Xianlong F, Yu Y, Hongyan L,
Qiang P and Haineng X: Inhibition of HeLa Cells by the combination
of Thioridazine and Oncolytic Adenovirus ZD55-TRAIL and the
exploration of its mechanism. Chinese J Cell Biol. 36:595–601.
2014.
|
